IFNA1 and systemic lupus erythematosus: Although glucocorticoid use is common among patients with SLE with an elevated IFNGS expression [96], type I interferon inhibition with anifrolumab reduced the need for glucocorticoid use in patients with SLE [50,51,52], highlighting the glucocorticoid-sparing capability of targeted anti-IFN therapies for some patients.